Menu
Explore Our Trials
Gateway for Cancer Research is one of the only nonprofits that exclusively funds innovative Phase I and Phase II cancer clinical trials for patients of all ages, regardless of cancer type. At the forefront of research and discovery, these early-phase trials are the first step in evaluating new cancer drugs, treatments, and therapies.
Results 1-10 of 18
Brain Cancer
Targeting Cytomegalovirus as a Novel for Immunotherapy of Glioblastoma Multiforme
Targeting Cytomegalovirus as a Novel for Immunotherapy of Glioblastoma Multiforme Glioblastomas (GBM) are tumors of the brain that are highly malignant. They are difficult to treat. Therapy usually includes radiation and chemotherapy. The median survival rate is about 14.6 months with less than 10% of the patients surviving five years or longer. Cytomegalovirus (CMV) has […]
Shiao-Pei Weathers, MD
The University of Texas MD Anderson Cancer Center
All Cancers
Role of Microbiome in the Realm of Immune Checkpoint Inhibitor Induced GI Complications in the Cancer Population
Role of Microbiome in the Realm of Immune Checkpoint Inhibitor Induced GI Complications in the Cancer Population (Phase I) Summary: Gastrointestinal (GI) complications due to immune checkpoint inhibitor (ICPI) therapy can be a severe side-effect that can be life-threatening for cancer patients. In 30-50% of cases, the standard therapy to treat these GI complication does […]
Yinghong Wang, MD
The University of Texas MD Anderson Cancer Center
Skin Cancer
Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients with Fanconi Anemia
Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients with Fanconi Anemia Patients who respond well to interventions for their childhood cancers may face other aggressive cancers in young adulthood. While 80-90% of children with Fanconi anemia respond to hematopoietic cell transplantation (HCT), they have a 500- to 700- fold higher incidence of squamous cell carcinoma […]
Dr. Parinda Mehta
Cincinnati Children's Hospital Medical Center
Breast Cancer
Predictive Biomarkers of New Experimental Agents Utilizing Reverse Phase Protein Microarray in Patients with Stage II and III Breast Cancer
Precision Medicine: Identification of Predictive Biomarkers of Several New Experimental Agents Utilizing Reverse Phase Protein Microarray (RPPA) in Patients with Stage II and III Breast Cancer (Phase II) Summary: This trial is building on the Phase I I-SPY-2 trial which identified several biomarkers that predicted effective response rates to a group of therapeutic agents. Dr. Petricoin and […]
Emanuel Petricoin, PhD
George Mason University
Renal Cancer
Pilot Study on the Biologic Effect of CBM588 in Combination with Nivolumab and Ipilimumab for Patients with Metastatic Renal Cell Carcinoma
Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination with Nivolumab/Ipilimumab for Patients with Metastatic Renal Cell Carcinoma Summary: Metastatic renal cell carcinoma (mRCC) is difficult to treat, even with the encouraging combination of nivolumab and ipilimumab immunotherapy drugs. Only 42% of patients respond to this therapy, and recent studies suggest an imbalance […]
Sumanta Pal, MD
City of Hope Comprehensive Cancer Center
Breast Cancer
Novel Use of Tetrathiomolybdate in Combination with Capecitabine in Patients with Triple Negative Breast Cancer
Novel Use of Tetrathiomolybdate in Combination with Capecitabine in Patients with Triple Negative Breast Cancer (Phase I/II) Summary: This combination Phase I/II trial will test the safety and efficacy of adding tetrathiomolybdate to the standard chemotherapy (capecitabine) for women diagnosed with triple negative breast cancer (TNBC). Phase I will focus on the safety of this […]
Linda Vahdat, MD, MBA
Memorial Sloan Kettering Cancer Center
Breast Cancer
Novel Use of Sacituzumab Govitecan with and without Pembrolizumab in Patients with HRP and HER2- Metastatic Breast Cancer
Novel Use of Sacituzumab Govitecan with and without Pembrolizumab in Patients with Hormone Receptor-Positive (HR+) / HER2- Metastatic Breast Cancer (Phase II) Summary: This trial is testing the effectiveness, safety, and tolerability of the novel combination of two drugs (sacituzumab govitecan and pembrolizumab) for patients diagnosed with HR+ / HER2- metastatic breast cancer. Patients will […]
Sara Tolaney, MD, MPH
Dana-Farber Cancer Institute
Pediatric Osteosarcoma
Novel Use of Regorafenib in Combination with Nivolumab in Patients with Recurrent or Refractory Osteosarcoma
Novel Use of Regorafenib in Combination with Nivolumab in Patients with Recurrent or Refractory Osteosarcoma Summary: Dr. Navid and team are examining if the addition of an immunotherapy drug (nivolumab) increases the effectiveness of a chemotherapy regimen (regorafenib) for patients age 5 years or older diagnosed with recurrent or refractory osteosarcoma. Patients at SARC subsites throughout the US will randomly […]
Fariba Navid, MD
Children's Hospital Los Angeles
Pancreatic Cancer
Novel Use of Pepinemab in Combination with Nivolumab and FOLFIRINOX Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma
Novel Use of Pepinemab and Nivolumab and FOLFIRINOX Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma (Phase Ib/II) Summary: Dr. Linehan’s trial is examining the use of a dual immunotherapy approach in combination with standard chemotherapy to treat inoperable and locally advanced pancreatic ductal cancer (PDAC). The dual immunotherapy drugs, nivolumab and pepinemab, will activate the immune system […]
David Linehan, MD
University of Rochester
Pediatric Rare Cancer
Novel Use of Nivolumab in Combination with Ipilimumab in Pediatric Patients with Relapse or Refractory INI1-Negative Cancers
Novel Use of Nivolumab and Ipilimumab in Pediatric Patients with Relapse or Refractory INI1-Negative Cancers (Phase II) Summary: In this trial, Dr. Forrest and team are using a dual immunotherapy approach to treat pediatric patients with recurrent or relapsed INI1-negative cancers. This group of cancers is both rare and aggressive, resulting in a poor prognosis […]
Suzanne Forrest, MD
Dana-Farber Cancer Institute
